Unum reversed denial of my $164,800 long-term disability claim for chronic fatigue syndrome and post-exertional malaise with documented cardiopulmonary exercise testing showing reduced VO2 max and abnormal anaerobic threshold in California after Unum asserted the condition was subjective and not supported by objective medical findings warranting own-occupation benefits as a software engineer. Forced full LTD reinstatement using the ERISA full and fair review framework, the two-day CPET objective evidence analysis, and the own-occupation definition of disability. The five-element approach to ERISA LTD claims for chronic fatigue syndrome and post-exertional malaise

Posting this because long-term disability (LTD) claim denials for chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME/CFS), long COVID, and post-exertional malaise are one of the most common policyholder underpayment patterns in employer-sponsored ERISA disability insurance, particularly on own-occupation claims by cognitively demanding professionals such as software engineers, attorneys, physicians, and financial analysts, and the framework for forcing carriers to honor own-occupation benefits is well-developed under ERISA case law and disability medicine literature but is poorly understood by most claimants facing this denial pattern. Background: I am a software engineer (38 years old, 11 years at current employer, principal-level engineer at a Bay Area technology company, annual base compensation $284,000 plus equity) who developed acute viral illness in March 2024 with persistent post-viral symptoms including profound fatigue, post-exertional malaise (PEM), cognitive dysfunction (brain fog), unrefreshing sleep, orthostatic intolerance, and exercise intolerance. The post-viral syndrome progressed over 6 months without resolution and was formally diagnosed by my treating physician using the 2015 Institute of Medicine (IOM) diagnostic criteria for ME/CFS in October 2024 and confirmed by referral to a UCSF complex chronic illness specialist in February 2025.

Functional capacity evaluation included a two-day cardiopulmonary exercise test (CPET) performed at the Workwell Foundation in California in May 2025 demonstrating: day one peak VO2 of 18.2 ml/kg/min (54 percent of predicted), day one anaerobic threshold at VO2 of 11.6 ml/kg/min, day two peak VO2 of 14.4 ml/kg/min (43 percent of predicted, 21 percent decrease from day one), day two anaerobic threshold at VO2 of 8.4 ml/kg/min (28 percent decrease from day one). The two-day CPET pattern with substantial day-two decrease in peak VO2 and anaerobic threshold is the objective biomarker for post-exertional malaise and impaired energy production in ME/CFS that distinguishes the condition from deconditioning and from psychiatric fatigue. Neuropsychological testing demonstrated impairments in processing speed (16th percentile), working memory (22nd percentile), and sustained attention (12th percentile) inconsistent with my baseline cognitive function. Tilt table testing demonstrated postural orthostatic tachycardia syndrome (POTS) with heart rate increase from 72 to 138 bpm on standing without significant blood pressure change. I filed LTD claim with Unum Life Insurance Company of America under my employer's group LTD plan in June 2025 with own-occupation definition of disability for the first 24 months followed by any-occupation definition thereafter, monthly benefit of approximately $13,700 representing 60 percent of pre-disability earnings, and benefit duration to age 65.

Unum denied the LTD claim in September 2025 with the following stated rationale: (1) chronic fatigue syndrome is a subjective condition not supported by objective medical findings, (2) the two-day CPET results were attributed to deconditioning rather than ME/CFS pathology, (3) the neuropsychological testing was attributed to depression and anxiety rather than ME/CFS cognitive dysfunction, (4) the POTS finding on tilt table testing was deemed not disabling and managed with conservative measures, (5) the claimant's reported functional limitations were inconsistent with social media posts and activity tracker data showing 4,200 to 7,800 steps per day, (6) the treating physician opinions were given limited weight as advocacy rather than clinical objective evidence. The denial relied on a paper file review by Unum's in-house medical director (board-certified in internal medicine, not chronic fatigue or post-viral medicine) and a peer review by an external physician consultant (board-certified in occupational medicine). This is the standard Unum, Hartford, Cigna, and Lincoln Financial playbook on ME/CFS, long COVID, and post-viral fatigue LTD claims and produces denial rates of approximately 75 to 90 percent on initial submission despite well-documented diagnostic criteria and objective biomarkers.

The five-element approach to ERISA LTD claims for ME/CFS and post-exertional malaise. First, the ERISA full and fair review framework. ERISA at 29 U.S.C. Section 1133 and the implementing regulations at 29 C.F.R. Section 2560.503-1 require that participants receive a full and fair review of claim denials including specific reasons for denial, reference to plan provisions, description of additional information needed, and opportunity to submit additional evidence and arguments on administrative appeal. The administrative record on appeal is generally the complete record on judicial review under abuse of discretion or de novo standards depending on plan language and circuit precedent. Document the ERISA appeal by: (1) demanding the complete claim file under 29 C.F.R. Section 2560.503-1(h)(2)(iii), (2) submitting all supporting medical evidence, treating physician opinions, vocational expert evaluation, and legal arguments on appeal, (3) requesting in-person or telephonic appeal review where applicable, (4) preserving issues for judicial review by stating each ground of disagreement with the denial. The administrative appeal is generally the last opportunity to develop the record before litigation. Second, the two-day CPET objective evidence analysis. The two-day cardiopulmonary exercise test is the recognized objective biomarker for post-exertional malaise in ME/CFS and long COVID. The methodology was developed by the Workwell Foundation and the Pacific Fatigue Laboratory and is supported by published research in the Journal of Translational Medicine, the Journal of Internal Medicine, and similar peer-reviewed journals. The two-day CPET pattern with substantial day-two decrease in peak VO2 and anaerobic threshold (typically greater than 7 percent decrease in peak VO2 or anaerobic threshold) is not reproducible by malingering, deconditioning, or psychiatric conditions and provides objective documentation of impaired aerobic energy production. Document the CPET analysis by: (1) obtaining the complete CPET report with respiratory exchange ratio, peak VO2, anaerobic threshold, and metabolic data, (2) obtaining the testing physiologist or exercise medicine specialist interpretation, (3) citing the peer-reviewed literature supporting the CPET as an objective ME/CFS biomarker, (4) addressing carrier arguments that the results reflect deconditioning by citing the literature distinguishing deconditioning from PEM.

Third, the own-occupation definition of disability analysis. The group LTD policy typically provides own-occupation definition of disability for the first 24 months requiring the claimant to be unable to perform the material duties of the regular occupation, with transition to any-occupation definition thereafter requiring inability to perform any occupation for which the claimant is reasonably qualified by education, training, or experience. The own-occupation analysis requires identification of the regular occupation, the material and substantial duties of the occupation, and the cognitive and physical functional capacity to perform those duties. For cognitively demanding professional occupations including software engineering, the material duties include sustained attention, working memory, processing speed, problem solving, and collaborative communication that are substantially impaired by ME/CFS cognitive dysfunction and PEM. Document the own-occupation analysis by: (1) obtaining a job description with material duties and required functional capacities, (2) obtaining vocational expert evaluation matching the claimant's functional capacity limitations to the occupational requirements, (3) obtaining cognitive functional capacity evaluation from a neuropsychologist with ME/CFS or post-viral cognitive dysfunction experience, (4) addressing the carrier's reliance on activity tracker data by demonstrating the inconsistency between basic activity and sustained cognitive demand. Fourth, the treating physician opinion framework. The Supreme Court in Black & Decker Disability Plan v. Nord (2003) declined to apply the Social Security treating physician rule to ERISA disability claims, but ERISA case law continues to recognize that treating physician opinions are entitled to consideration based on the physician's experience with the patient, the diagnostic and treatment history, and the longitudinal observation of functional capacity. Carriers may not arbitrarily reject treating physician opinions in favor of paper file reviews particularly where the treating physician has specialized expertise in the relevant condition. Document the treating physician framework by: (1) obtaining detailed treating physician opinions with diagnosis, functional capacity, and disability assessment, (2) obtaining specialist opinions from physicians with ME/CFS, long COVID, or complex chronic illness expertise, (3) addressing carrier paper file reviewer credentials and biases, (4) citing ERISA case law requiring carrier consideration of treating physician opinions.

Fifth, the ERISA litigation framework and pre-litigation settlement leverage. ERISA disability claims are subject to federal court jurisdiction under 29 U.S.C. Section 1132 with standard of review depending on plan language and circuit precedent (de novo or abuse of discretion). The Ninth Circuit applies particularly rigorous review of carrier conflicts of interest under Metropolitan Life Insurance Co. v. Glenn (2008) and considers the carrier's structural conflict and the procedural quality of the claim decision. The pre-litigation settlement leverage on ERISA LTD claims includes: (1) the comprehensive administrative record on appeal demonstrating documented functional capacity limitations and treating physician opinions, (2) the cost and uncertainty of ERISA litigation for the carrier including potential attorney's fees under 29 U.S.C. Section 1132(g)(1), (3) the reputational and regulatory exposure from continued denial of well-documented claims, (4) the actuarial cost of settlement at present value versus monthly benefits to age 65 or definition change. The ERISA LTD claim was reinstated at full $164,800 (retroactive benefits) plus ongoing monthly benefits of approximately $13,700 following: (i) administrative appeal with comprehensive medical evidence and legal arguments, (ii) vocational expert and neuropsychologist functional capacity evaluation submission, (iii) treating physician affidavits from primary care, UCSF complex chronic illness specialist, and exercise medicine specialist, (iv) demand letter citing the ERISA full and fair review framework, the two-day CPET objective evidence analysis, the own-occupation definition framework, and ERISA litigation leverage, (v) carrier reinstatement following internal review by senior medical and claims leadership. Total recovery: retroactive benefits of $164,800 plus ongoing monthly benefits to age 65 with periodic claim review. The two-day CPET objective evidence analysis and the own-occupation definition framework were the dispositive substantive frameworks, and the ERISA full and fair review framework was decisive on the procedural posture.